Interview with Martin Stapf, Global BU Director Oncology, Hikma Pharma
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm…
Hikma Pharma
Last updated: 13.02.2014
Address: Lochhamer Schlag 17, 82166 Gräfelfing,Germany
Tel: +49 (0)89 45 45 0-0
Web: www.ribosepharm.de or www.hikma.com
Company description
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (”MENA”) region, the United States and Europe. Currently, the group sells 369 pharmaceutical products in 767 dosage strengths and forms in 49 countries. 40 of our products are sold under promotion and distribution agreements with, or licenses from, 16 originator pharmaceutical companies and three generic pharmaceutical companies.Its listing on the London Stock Exchange in November 2005 marked the beginning of an exciting new phase in the Company’s development. The financial flexibility that Hikma gained through the listing leaves it in a good position to grow, both organically and through acquisitions.The group’s strategy for growth is to build a strong and diverse product portfolio; to expand its geographic reach; to develop and leverage global research and development capabilities and API sourcing strengths; and to continue to maintain the very high standards of manufacturing capabilities.The german company Ribosepharm, founded in 1983, was a mid-sized pharmaceutical company who boast 20 years of commitment to oncology with its products in cancer therapy. In January 2007 it became a member of the Hikma Group via acquisition.
Products and services
Interviews
Related
Europe / Top 5 Pharma R&D Spenders
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest…
Europe / Health Technology Assessment in the EU: Back and Forth in Giant Strides
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy…
Europe / New EFPIA President Hubertus von Baumbach on Building Back Better from COVID & a Healthier European Future
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of…
Germany / Merck KGaA Expecting More COVID-Related Deals; Digital Health Woes; CureVac Vaccine Potential vs Variants
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck…
Germany / Highest Honours for BioNTech Founders; Bayer’s Growth Predictions; Merck Making Further French Investments
A roundup of some of the most important recent news from German pharma, including state honours for the founders of…
Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness…
Germany / The Biotech Behind Pfizer’s COVID-19 Vaccine Candidate
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant…
Pharma Faces / Teresa Rodó, Head of Global Healthcare Operations, Merck
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to…
Merck KGaA / Big-Ticket Investments in Manufacturing Scale & Digital Innovation
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
News Roundup / German Pharma: February 2020
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as…
